ActivistsInvestorsTrumpPoliticiansSerenityCitriniBurrySemianalysisSwingTradeArbitrageSearch

$BCAX:NASDAQ · Bicara Therapeutics Inc - US

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.

More about this company

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Sector: health

Conviction from: NASDAQ

52-week range: 7.8730.99

2 tracked filer(s) hold this · 2 opened, 0 added, 0 trimmed in 30-SEP-2026

Aggregate 13FScore 68 — mean of 2 scored holder(s) · buyers (new/add) avg 68. Higher = the smart money in this name has the better track record.

Filer13FScoreThis quarterSharesValue% of their book
Paul Tudor Jones / Tudor61New buy33,086$615,7300.0%
Steve Cohen / Point7275New buy627,108$11,670,4800.0%

Beyond 13F — activists, insiders, politicians & research

Activist 13D filings daily digest →

FiledFormActivist% of classConviction
2026-03-02SCHEDULE 13D/ARA CAPITAL MANAGEMENT, L.P.11.5%Highfiling

Insider open-market buys daily digest →

FiledInsiderRoleSharesValue
2026-03-02RA CAPITAL MANAGEMENT, L.P.director+10%-owner300,000$4,800,000Form 4

Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.